Premium
Interleukin‐1 receptor antagonist (IL‐1ra) modulates endothelial cell proliferation
Author(s) -
Dewberry Rachael M.,
King Andrea R.,
Crossman David C.,
Francis Sheila E.
Publication year - 2008
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2008.02.021
Subject(s) - interleukin 1 receptor antagonist , interleukin 1 receptor, type i , interleukin 1 receptor, type ii , interleukin 12 receptor, beta 1 subunit , receptor antagonist , biology , retinoblastoma protein , cell growth , interleukin , receptor , microbiology and biotechnology , endocrinology , cancer research , medicine , antagonist , cytokine , immunology , cell cycle , cell , biochemistry , interleukin 5
Endothelial cell (EC) lifespan controlled by the IL‐1 family of cytokines is an important determinant of susceptibility to artery wall disease. Here we show that EC lacking intracellular interleukin‐1 receptor antagonist (IL‐1ra) have a reduced lifespan compared to controls. Over expression of IL‐1ra enhanced proliferation via cyclin dependent kinase 2 activity and retinoblastoma protein phosphorylation. This was not seen in EC lacking IL‐1 receptor 1 (IL‐1 signalling ability), nor apparent using other stimuli e.g. TNFα. These data suggest that IL‐1ra has a specific and receptor‐dependent function to control the growth and lifespan of EC.